A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Smoldering Multiple Myeloma (SMM)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 40 (final count)
- Started
- Jan 30, 2024
- Main results expected
- Jan 25, 2033
- Fully finished
- Jan 25, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency of Adverse Events of Special Interest (AESI) during the safety run-in observation period
Measured over: Up to 35 days
Frequency of Treatment-Emergent Adverse Events (TEAEs) during the safety run-in observation period
Measured over: Up to 35 days
Severity of TEAEs during the safety run-in observation period
Measured over: Up to 35 days
Complete Response (CR) as determined by the investigator
Measured over: Up to 7 years
Minimal Residual Disease (MRD) negativity
Measured over: At 12 months
MRD negativity
Measured over: At 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05955508 · record last updated 2026-04-13 · checked 2026-11-09 15:47 UTC